Major milestone reached with the sale of the 100th Cyclone® KIUBE cyclotron!

We have reached the notable milestone of the sale of the 100th Cyclone® KIUBE cyclotron earlier this year.

It demonstrates the world leading position of this machine on the mid energy cyclotron market.

Let’s see through the eyes of our long-term users of IBA cyclotrons

  • IBA cyclotron cyclone KIUBE
  • IBA cyclotron cyclone KIUBE
Herlev hospital IBA cyclotron

Lars Thorbjørn Jensen, Head of Department of Clinical Physiology and Nuclear Medicine at Herlev Hospital, University of Copenhagen, Denmark, said: “15 years ago we acquired our first cyclotron, the IBA Cyclone® 18/9. It has proven to be very efficient in our daily work, when we sought to acquire another cyclotron, the IBA Cyclone® KIUBE was the logical choice. It meets all our requirements, including eight ports, high yield, and low standby energy consumption.”

Maria Vosjan, Managing Director of BV Cyclotron VU, University of Amsterdam, The Netherlands, said: “When we started our new radiopharmacy project two years ago, the Cyclone® KIUBE 300, with its unique versatility of 8 exit ports and unparalleled production capability up to 30 Curie 18F in one run, was the obvious choice for us.”

The Cyclone® KIUBE cyclotron is recognized for its superior production capacity, reaching up to 300 Microamperes (µA) proton current, the highest in the industry. This high production capacity has made it the preferred choice for many institutions and companies in more than 40 countries. It has the widest range of PET radioisotopes production including Fluorine-18 (18F), Gallium-68, Zirconium-89, Carbon-11, and many others used in oncology, cardiology and neurology imaging.

Bruno Scutnaire, President at IBA RadioPharma Solutions, commented: “We are very proud to have reached this milestone in such a short period of time. The sale of our 100th Cyclone® KIUBE cyclotron to a long-standing user such as the Herlev Hospital, testifies the trust our users place in us and the quality of our products. Since its inception, it has been a real game changer on the cyclotron market thanks to its compact design, as well as its high performance enabling our customers to produce multiple isotopes for the diagnosis of severe diseases. All of this with a lower electrical consumption reaffirming IBA’s commitment to develop solutions that meet the market’s needs while being more sustainable.”